Cutaneous B-Cell Lymphoma: Treatment Options
First-line treatment options for cutaneous B-cell lymphoma depend on the type of CBCL, the patient’s symptoms and overall health, and the stage of the disease.
Treatment options for primary cutaneous follicle center lymphoma and cutaneous marginal zone B-cell lymphoma, depending on the number of lesions present, include:
- Observation without active treatment which is known as “active surveillance” (also known as “watch and wait” or “watchful waiting”). During this period, regular follow-up with your healthcare team is required.
- Radiation Therapy
There is no known standard treatment strategy for the more aggressive types of CBCL, such as cutaneous diffuse large B-cell lymphoma, leg type. For single tumors, radiation with or without chemotherapy is recommended. Similar to other B-cell NHLs, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without radiation therapy is commonly used to treat CBCL that has spread and become a more generalized lymphoma. Clinical trials are also often recommended. Although all of these treatments usually result in disease remission, relapse is common.
To learn about treatments under investigation for CBCL, download the Cutaneous B-Cell Lymphoma Fact Sheet.